South Korea
· Delayed Price · Currency is KRW SCM Lifescience Statistics
Total Valuation
SCM Lifescience has a market cap or net worth of KRW 43.39 billion. The enterprise value is 40.96 billion.
| Market Cap | 43.39B |
| Enterprise Value | 40.96B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
SCM Lifescience has 20.47 million shares outstanding. The number of shares has increased by 40.76% in one year.
| Shares Outstanding | 20.47M |
| Shares Change (YoY) | +40.76% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 17.00% |
| Owned by Institutions (%) | 0.03% |
| Float | 16.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 43.32 |
| PB Ratio | 2.90 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -2.18 |
| EV / Sales | 40.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.61 |
Financial Position
The company has a current ratio of 6.37, with a Debt / Equity ratio of 0.27.
| Current Ratio | 6.37 |
| Quick Ratio | 5.74 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.36 |
| Interest Coverage | -58.58 |
Financial Efficiency
Return on equity (ROE) is -124.29% and return on invested capital (ROIC) is -38.14%.
| Return on Equity (ROE) | -124.29% |
| Return on Assets (ROA) | -35.81% |
| Return on Capital (ROIC) | -38.14% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.05 |
| Inventory Turnover | 1.60 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -12.30% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -12.30% |
| 50-Day Moving Average | 2,235.40 |
| 200-Day Moving Average | 2,745.48 |
| Relative Strength Index (RSI) | 46.13 |
| Average Volume (20 Days) | 119,133 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SCM Lifescience had revenue of KRW 1.00 billion and -18.75 billion in losses. Loss per share was -914.06.
| Revenue | 1.00B |
| Gross Profit | 374.27M |
| Operating Income | -12.22B |
| Pretax Income | -18.75B |
| Net Income | -18.75B |
| EBITDA | -11.47B |
| EBIT | -12.22B |
| Loss Per Share | -914.06 |
Balance Sheet
The company has 6.55 billion in cash and 4.11 billion in debt, giving a net cash position of 2.43 billion or 118.88 per share.
| Cash & Cash Equivalents | 6.55B |
| Total Debt | 4.11B |
| Net Cash | 2.43B |
| Net Cash Per Share | 118.88 |
| Equity (Book Value) | 14.97B |
| Book Value Per Share | 731.79 |
| Working Capital | 6.31B |
Cash Flow
In the last 12 months, operating cash flow was -11.17 billion and capital expenditures -187.87 million, giving a free cash flow of -11.36 billion.
| Operating Cash Flow | -11.17B |
| Capital Expenditures | -187.87M |
| Free Cash Flow | -11.36B |
| FCF Per Share | -555.02 |
Margins
| Gross Margin | 37.29% |
| Operating Margin | -1,217.93% |
| Pretax Margin | -1,867.92% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -1,131.92% |
Dividends & Yields
SCM Lifescience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -40.76% |
| Shareholder Yield | -40.76% |
| Earnings Yield | -43.12% |
| FCF Yield | -26.18% |
Stock Splits
The last stock split was on September 15, 2023. It was a forward split with a ratio of 1.2.
| Last Split Date | Sep 15, 2023 |
| Split Type | Forward |
| Split Ratio | 1.2 |
Scores
SCM Lifescience has an Altman Z-Score of -7.05. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.05 |
| Piotroski F-Score | n/a |